Thus, based on our data the threshold of <5%, which is used by IWG-PM, ICC and WHO 2022, is not required if presence of del(5q) and RUNX1 mutation are exclusion criteria for the SF3B1 entity. Here, SF3B1 is linked to intrahepatic cholangiocarcinoma.